BiotechTube

Novartis MenACWY-CRM + Saline Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningococcal Disease

Conditions

Meningococcal Disease, Meningococcal Meningitis

Trial Timeline

Dec 1, 2010 → Mar 1, 2011

NCT ID
NCT01274897

About Novartis MenACWY-CRM + Saline Placebo

Novartis MenACWY-CRM + Saline Placebo is a phase 3 stage product being developed by Novartis for Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01274897. Target conditions include Meningococcal Disease, Meningococcal Meningitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01274897Phase 3Completed

Competing Products

20 competing products in Meningococcal Disease

See all competitors
ProductCompanyStageHype Score
RotaTeq® + NeisVac-C®MerckPhase 3
77
Meningococcal C conjugate vaccineNovartisApproved
85
Meningococcal (group B) multicomponent recombinant adsorbed vaccine. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)NovartisPhase 2
52
Meningococcal ACWY-CRM conjugate vaccine + Meningococcal ACWY-PS polysaccharide vaccineNovartisPhase 3
77
1a - rMenB+OMV NZ and routine vaccines + 1b - rMenB+OMV NZ and routine vaccines + 2a - Routine and rMenB+OMV NZ vaccines + 2b - rMenB+OMV NZ and routine vaccines + 3a - rMenB+OMV NZ and routine vaccines + 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations + 4a- rMenB+OMV NZ and routine vaccines + 4b - rMenB+OMV NZ and routine vaccinesNovartisPhase 3
77
MenACWY-CRMNovartisPre-clinical
23
Meningococcal C conjugate vaccineNovartisApproved
85
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
85
rMenB + rMenB+OMV NZNovartisPhase 2
52
Typhoid Vi Polysaccharide Vaccine + Yellow Fever Vaccine + Japanese Encephalitis Vaccine + Rabies Vaccine + MenACWY-CRM VaccineNovartisPhase 3
77
rMenB+OMV NZNovartisPhase 3
77
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
77
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + TdapNovartisPhase 2
52
MenACWY-CRMNovartisPhase 3
77
rMenB + rMenB+OMVNovartisPhase 2
52
MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMVNovartisPhase 2
52
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.NovartisPhase 2
52
MenABCWY+OMV + MenABCWY+¼OMV + PlaceboNovartisPhase 2
52
rMenB+OMV NZ + PlaceboNovartisPhase 2/3
65
rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccineNovartisPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85